PE20250797A1 - Derivado de peptido ciclico, metodo para su produccion y composicion - Google Patents

Derivado de peptido ciclico, metodo para su produccion y composicion

Info

Publication number
PE20250797A1
PE20250797A1 PE2025000305A PE2025000305A PE20250797A1 PE 20250797 A1 PE20250797 A1 PE 20250797A1 PE 2025000305 A PE2025000305 A PE 2025000305A PE 2025000305 A PE2025000305 A PE 2025000305A PE 20250797 A1 PE20250797 A1 PE 20250797A1
Authority
PE
Peru
Prior art keywords
optionally substituted
composition
independently
cyclic peptide
peptide derivative
Prior art date
Application number
PE2025000305A
Other languages
English (en)
Spanish (es)
Inventor
Kohei Matsumoto
Yuma Karita
Kosuke Yasui
Shichidai TANABE
Takeshi Shosu
Original Assignee
Dks Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dks Co Ltd filed Critical Dks Co Ltd
Publication of PE20250797A1 publication Critical patent/PE20250797A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/12Cyclic peptides with only normal peptide bonds in the ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06078Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0812Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1002Tetrapeptides with the first amino acid being neutral
    • C07K5/1016Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0618Cells of the nervous system
    • C12N5/0622Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/30Organic components

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PE2025000305A 2022-08-04 2023-08-04 Derivado de peptido ciclico, metodo para su produccion y composicion PE20250797A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2022124810 2022-08-04
JP2022159060 2022-09-30
PCT/JP2023/028632 WO2024029630A1 (ja) 2022-08-04 2023-08-04 環状ペプチド誘導体とその製造方法および組成物

Publications (1)

Publication Number Publication Date
PE20250797A1 true PE20250797A1 (es) 2025-03-14

Family

ID=89849507

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2025000305A PE20250797A1 (es) 2022-08-04 2023-08-04 Derivado de peptido ciclico, metodo para su produccion y composicion

Country Status (12)

Country Link
US (1) US20260035407A1 (https=)
EP (1) EP4567042A1 (https=)
JP (1) JPWO2024029630A1 (https=)
KR (1) KR20250044905A (https=)
CN (1) CN119731193A (https=)
AU (1) AU2023317392A1 (https=)
CO (1) CO2025001948A2 (https=)
IL (1) IL318676A (https=)
MX (1) MX2025001373A (https=)
PE (1) PE20250797A1 (https=)
TW (1) TW202423948A (https=)
WO (1) WO2024029630A1 (https=)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
DE69839355T2 (de) 1997-07-29 2009-06-04 Alcon Laboratories, Inc., Fort Worth Ophthalmische Zusammensetzungen enthaltend Galaktomannanpolymere und Borat
AU2483599A (en) 1998-01-29 1999-08-16 Sepracor, Inc. Pharmaceutical uses of optically pure (-)-bupropion
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
EP1654002B2 (en) 2003-08-07 2014-01-29 Allergan, Inc. Compositions for delivery of therapeutics into the eyes
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
WO2016047638A1 (ja) * 2014-09-24 2016-03-31 国立大学法人岩手大学 環状ペプチド誘導体とその製造方法および組成物
JP7486328B2 (ja) * 2020-03-05 2024-05-17 株式会社バイオコクーン研究所 神経突起伸長促進剤、神経細胞の樹状突起発現促進剤、及び神経栄養因子様作用物質
JP7695662B2 (ja) * 2020-11-02 2025-06-19 公立大学法人大阪 環状ペプチド誘導体の製造方法及び環状ペプチド化合物の製造方法

Also Published As

Publication number Publication date
MX2025001373A (es) 2025-03-07
CN119731193A (zh) 2025-03-28
JPWO2024029630A1 (https=) 2024-02-08
IL318676A (en) 2025-03-01
KR20250044905A (ko) 2025-04-01
AU2023317392A9 (en) 2026-02-12
US20260035407A1 (en) 2026-02-05
TW202423948A (zh) 2024-06-16
WO2024029630A1 (ja) 2024-02-08
CO2025001948A2 (es) 2025-03-06
EP4567042A1 (en) 2025-06-11
AU2023317392A1 (en) 2025-02-20

Similar Documents

Publication Publication Date Title
AR117139A1 (es) Derivados de piridooxazinona como inhibidores de monoacilglicerol ligasa (magl)
CL2021002883A1 (es) Moduladores de thr-ß y métodos de uso de estos
ECSP056016A (es) Nuevos derivados de 2-piridinacarboxamida
AR119698A2 (es) Compuesto amida n-urea sustituida derivado de aminoácido
AR064874A1 (es) Derivados de hexahidro y tetrahidropterinas,composiciones farmaceuticas que los contienen y usos de las mismas en trastornos cardiovasculares y psiquiatricos entre otros
AR087328A1 (es) Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak
AR079164A1 (es) Derivados heterociclicos de indol, composiciones farmaceuticas que los comprenden y uso de los mismos para la profilaxis o tratamiento de enfermedades alergicas, inflamatorias y/o autoinmunes.
AR055100A1 (es) Benzimidazoles triciclicos y su uso como moduladores de receptores metabotropicos de glutamato
AR070828A1 (es) Derivados de azetidina y ciclobutano como inhibidores de jak
AR063684A1 (es) Derivados de 4, 4´-bifenildiilbis(1h-imidazol-5, 2-diil) como inhibidores del virus de la hepatitis c, composicion que los comprende y su uso para tratar una infeccion con vhc.
AR085960A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
AR086983A1 (es) Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
CO6170361A2 (es) Composiciones y metodos para modular receptores de c-kit y pdgfr
CO5721006A2 (es) Derivados de pirazolo-quinazolina, proceso para su preparacion y su uso como inhibidores de quinasa
AR106472A1 (es) Inhibidores de acc y usos de los mismos
AR064389A1 (es) Derivados heterociclicos de nicotinamida utiles en el tratamiento de afecciones y enfermedades alergicas y respiratorias, y composiciones farmaceuticas que los contienen.
CO5640104A2 (es) Derivados de aminoisoxazol activos como inhibidores de quinasa
CR20110617A (es) Derivados aminobutíricos sustituidos como inhibidores de neprilisina
BR112015015812A2 (pt) derivados de pirimidina fundidos a pirido ou pirrolo como inibidores de autotaxina para tratamento de dor
CO5640152A2 (es) Composiciones farmaceuticas para inhibidores de la proteasa del virus de la hepatitis c
AR060318A1 (es) Isoindolonas potenciadoras de receptores metabotropicos de glutamato, composiciones farmaceuticas que las comprenden y el uso de las mismas en la fabricacion de un medicamento para el tratamiento de trastornos neurologicos y psiquiatricos.
AR076460A1 (es) Antagonistas del receptor cxcr3
AR022303A1 (es) Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion
AR059428A1 (es) Pirazoles para el tratamiento de enfermedades mediadas por la modulacion de los receptores de histamina h3 y una composicion farmaceutica que los comprende.
AR086086A1 (es) Derivados glucosidos y usos de los mismos